Halozyme - Making The Most Of ENHANZE Opportunities

Shares of Halozyme Therapeutics Inc. (HALO) are down 37% from their 52-week high of $59.46, recorded last December, and trade around $37..

Related Keywords

Bristol Myers Squibb ,Roche Phesgo ,Eli Lilly ,Pfizer ,Halozyme Therapeutics Inc ,Halozyme Therapeutics ,Horizon Therapeutics ,Viiv Healthcare ,Generalized Myasthenia ,Fda ,Gnoche ,Halo ,Enhanze ,Opdivo ,